BrandMemo | manage and share brands you love  Pharmamedix su Facebook  Pharmamedix su Twitter
 Home | News | About us | Comitato scientifico | Iscriviti | Utenti | Etica | Contenuti | Guida | Faq | Stage | Contatti
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Trimetoprim

Bactrim

Bibliografia - Quali fonti bibliografiche per Trimetoprim?


         

1. Agenzia Italiana del Farmaco - AIFA, Bactrim - Riassunto Caratteristiche di Prodotto, 2013, disponibile on line www.farmaci.agenziafarmaco.gov.it/bancadatifarmaci/

2. Amyes S.G., Young H.K., Trans. R. Soc. Trop. Med. Hyg., 1987, 81 (3), 504.

3. Andersen J.T. et al., Obstet. Gynecol. Int., 2013, 2013:364526. doi: 10.1155/2013/364526.

4. Ardiç I. et al., Turk. Kardiyol. Dern. Ars., 2009, 37 (6), 410.

5. Arola O. et al., Lancet, 1998, 351 (9109), 1102.

6. Briggs G.G. et al., Drug in Pregnancy and Lactation: A reference Guide to fetal and Neonatal Risk, 194, Lippincott Williams and Wilkins.

7. Brunton L.L. et al., Goodman & Gilman’s Manual of Pharmacology and Therapeutics, 2007, McGraw-Hill Professional.

8. Bushby S.R., J. Infect. Dis., 1973, 128 (Suppl.), 442.

9. Chan H.L. et al., Arch Dermatol., 1990, 126 (1), 43.

10. Chanarin I., England J.M., Br. Med. J., 1972, 1 (5801), 651.

11. Cheung H.T. et al., 1986, Biochemistry, 25 (8), 1925.

12. Crider K.S. et al., Arch. Pediatr. Adolesc. Med., 2009, 163 (11), 978.

13. Czeizel A.E. et al., Reprod. Toxicol., 2001, 15 (6), 637.

14. DuPont H.L. et al., NEJM, 1982, 307 (14), 841.

15. Ellenhorn M.J. et al., Ellenhorn’s Medical Toxicology, 1997, 2nd edition, Baltimor. MD: Williams and Wilkins.

16. Flensburg J., Skold O., J. Bacteriol., 1984, 159 (1), 184.

17. Flensburg J., Skold O., Eur. J. Biochem., 1987, 162 (3), 473.

18. Food and Drug Administration - FDA, Trimethoprim - Label information, 2012.

19. Food and Drug Administration - FDA, Bactrim - Label information, 2013.

20. Ford N. et al., J. Acquir Immune Defic. Syndr., 2014, 66 (5), 512.

21. Guidelines for Prevention and Treatment of Opportunistic Infection in HIV-Infected Adults and Adolescents, 2014 disponibile online http://AIDSinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0

22. Gillman M.A., Sandyk R., Ann. Intern. Med., 1985, 102 (4), 559.

23. Heckbert S.R., et al., Am. J. Epidemiol., 1990, 132 (2), 336.

24. Hernandez-Diaz S. et al., NEJM, 2000, 343 (22), 1608.

25. Hernandez-Diaz S. et al., Am. J. Epidemiol., 2001, 153 (10), 961.

26. Hoppu K., Arjomaa P., Chemotherapy, 1984, 30 (5), 283.

27. Jick H., Rev. Infect. Dis., 1982, 4 (2), 426.

28. Jaakkola T. et al., Basic Clin. Pharmacol. Toxicol., 2006, 99 (1), 44.

29. Joffe A.M. et al., Am. J. Med., 1989, 87 (3), 332.

30. Johnson M.P. et al., Pharmacotherapy, 1990, 10 (6), 413.

31. Kastrup J. et al., Br. J. Urol., 1985, 57 (3), 265.

32. Kobrinsky N.L., Ramsay N.K., Ann Intern. Med., 1981, 94 (6), 780.

33. Kosoglou T. et al., Clin. Pharmacol. Ther., 1988, 44 (4), 467.

34. Lacey R.W., Stokes A., J. Clin. Pathol., 1978, 31 (7), 700.

35. Lacey R.W., J. Antimicrob. Chemother., 1979, 5 (11), 75.

36. Lawson D.H., Jick H., Am. J. Med. Sci., 1978, 275 (1), 53.

37. Maki D.G. et al., J. Lab. Clin. Med., 1992, 119 (1), 11.

38. Matthews D.A. et al., J. Biol. Chem., 1985, 260 (1), 392.

39. Matthews D.A. et al., Biochemistry, 1986, 25 (15), 4194.

40. McEvoy G.K., American Hospital Formulary Service - Drug Information, 2002, Bethesda, American Society oh Health-System Pharmacists.

41. Medina I. et al., NEJM, 1990, 323 8129, 766.

42. Micromedex Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1.

43. Ministero della Salute, Malattia di Whipple, 2014, 24 ottobre online http://www.salute.gov.it/portale/salute/p1_5.jsp?lingua=italiano&id=204&area=Malattie_infettive

44. Muller M.P. et al., Clin. Nephrol., 2001, 55 (1), 80.

45. Naderer O. et al., Antimicrob. Agents Chemother., 1997, 41 (11), 2466.

46. Nelson J.D. et al., JAMA, 1976, 235 (12), 1239.

47. Niemi M. et al., Br. J. Clin. Pharmacol., 2004, 57 (4), 441.

48. Perazella M.A., Drug Saf., 2000, 22 (3), 227.

49. Petersen P. et al., Acta Med. Scand., 1985, 217 (4), 423.

50. Quinlivan E.P. et al., FASEB J., 2000, 14 (15), 2519.

51. Salter A. J., Rev. Infect., 1982, 4 (7), 196.

52. Santos F. et al., BJOG, 2011, 118 (11), 1374.

53. See S., Mumford J.M., Ann. Pharmacother., 2001, 35 (6), 694.

54. Skold O., Vet. Res., 2001, 32 (3-4), 261.

55. Sun Y et al., Pharmacoepidemiol. Drug Saf., 2014, 23 (10), 1076.

56. Then R.L., Angehrn P., Antimicrob. Agents Chemother., 1979, 15 (1), 1.

57. Thomas M.H., Gutterman L.A., J. Rheumatol., 1986, 13 (2), 440.

58. Then R.L., Rev. Infect. Dis., 1982, 4 (2), 261.

59. Trickett P.C. et al., J Infect Dis, 1973, 128 (Suppl.), 693.

60. Velazquez H. et al., Ann. Intern. Med., 1993, 119 (4), 296.